Skip to Content

ImmunityBio, Inc.

Securities Class Action

  • Date:
  • 5/26/2026
  • Company Name:
  • ImmunityBio, Inc.
  • Stock Symbol:
  • IBRX
  • Class Period:
  • FROM 1/19/2026 TO 3/24/2026
  • Status:
  • Filed
  • Filing Date:
  • 3/26/2026
  • Court:
  • U.S. District Court: Central California

Case Finder

Locate any case using the tools below.

Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, announces that a class action lawsuit has been filed against ImmunityBio, Inc. (“ImmunityBio” or the “Company”) (NASDAQ:IBRX) in the United States District Court for the Central District of California on behalf of all persons and entities who purchased or otherwise acquired ImmunityBio securities between January 19, 2026 and March 24, 2026, both dates inclusive (the “Class Period”). Investors have until May 26, 2026 to apply to the Court to be appointed as lead plaintiff in the lawsuit.

According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (1) Defendant Patrick Soon-Shiong materially overstated Anktiva's capabilities; and (2) as a result, defendants' statements about ImmunityBio's business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.
 
If you purchased or otherwise acquired ImmunityBio shares and suffered a loss, are a long-term stockholder, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker or Melissa Fortunato by email at investigations@bespc.com, telephone at (212) 355-4648, or by filling out the form below. There is no cost or obligation to you.
Contact Instructions
Please contact Brandon Walker or Melissa Fortunato by email at investigations@bespc.com with any questions about this case.
The individual or institution below (“Plaintiff”) has reviewed and agrees to the Bragar Eagel & Squire, P.C. (“BESPC”) retainer agreement and authorizes BESPC to prosecute an action on Plaintiff’s behalf under the federal securities laws or applicable state laws to recover damages on behalf of investors in ImmunityBio. BESPC will prosecute the action on a full contingency basis and will forward all costs and expenses.
 

Case Finder

Locate any case using the tools below.

You may share a link to this page on any of the sites listed below or send link via email: